ArticleArchives of dermatological research2025
New tool in our arsenal: efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study assesses the short-term therapeutic efficacy and safety of injectable platelet-rich fibrin (i-PRF) in managing androgenetic alopecia (AGA). AGA, a common genetic condition leading to hair loss, significantly affects the quality of life. Given the limited efficacy of existing treatments, there is an urgent need for novel therapeutic strategies. This study investigates the potential of i-PRF, a biotherapeutic agent enriched with growth factors and cell proliferation promoters, to enhance hair regeneration and ameliorate the microenvironment of hair follicles.
methodsA prospective, single-center study enrolled 30 AGA patients with inadequate responses to conventional treatments. Participants received six monthly i-PRF injections. Assessments included hair scoring (hair density, vellus hair percentage, and hair shaft diameter), treatment efficacy, physician's visual subjective scoring, scalp inflammation scoring (folliculitis, greasiness, dandruff, and itching), Dermatology Quality of Life Index (DLQI) scores, patient satisfaction scoring, and monitoring for adverse reactions post-injection.
resultsAt the 6-month mark, an 80% response rate was achieved, with significant improvements in hair loss and scalp symptoms as per hair scoring, physician's visual subjective scoring, scalp inflammation scoring, DLQI scoring, and patient satisfaction scoring compared to baseline.
conclusioni-PRF effectively enhances hair density and alleviates scalp symptoms in AGA patients, demonstrating notable therapeutic effects with minimal adverse reactions, offering a promising new avenue for AGA treatment.
Indexed as
Identifiers
40009221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.